Dr. Nayak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-2166Fax+1 617-632-4773
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2006 - 2009
New York Downtown HospitalResidency, Internal Medicine, 2004 - 2006
Grant Medical CollegeClass of 2002
Certifications & Licensure
FL State Medical License 2022 - Present
ME State Medical License Current
MA State Medical License 2011 - 2026
NY State Medical License 2011 - 2013
PA State Medical License 2009 - 2010- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
- Pembrolizumab, Ibrutinib and Rituximab in PCNSL Start of enrollment: 2020 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Novel Therapies for Primary Central Nervous System Lymphomas.Elisa Aquilanti, Elizabeth Herrity, Lakshmi Nayak
Current Neurology and Neuroscience Reports. 2024-12-01 - Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients.Fabio M Iwamoto, Shyam K Tanguturi, Lakshmi Nayak, Tony J Wang, Arati Desai
Clinical Cancer Research. 2024-11-08 - Masked Arginine Vasopressin Deficiency in a Kidney Transplant Recipient With Posttransplant Lymphoproliferative Disorder.Annie Liu, Lakshmi Nayak, Waihay J Wong, Inhye E Ahn, Naoka Murakami
Kidney International Reports. 2024-09-01
Lectures
- Turning the Corner in Relapsed/Refractory CNS Lymphoma: Applying Precision and Immune-Based...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with r...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Kazia Enters Clinical Collaboration with Dana-Farber Cancer Institute for Primary CNS LymphomaSeptember 22nd, 2020
The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in FundingNovember 8th, 2018
Immunotherapy Agent Yields Full and Partial Remissions in Aggressive Non-Hodgkin LymphomasDecember 5th, 2016- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
